NWAMAKA EMERUEM: Open Payments
NPI 1508366642 · VANCOUVER, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,410 in 63 payments from 9 companies in 2025. Trend: 2023 $1,930 · 2024 $1,945 · 2025 $1,410
Food & beverage: $1,404Education: $5
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $608 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $200 |
| Janssen Pharmaceuticals, Inc | 5 | $151 |
| Alkermes, Inc. | 7 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $102 |
| E.R. Squibb & Sons, L.L.C. | 3 | $72 |
| Neurocrine BioSciences, Inc. | 3 | $67 |
| Axsome Therapeutics, Inc. | 2 | $62 |
| Corium, LLC | 1 | $32 |
Products named: VRAYLAR, CAPLYTA, ARISTADA, TRINTELLIX, COBENFY, INGREZZA, Auvelity, INVEGA SUSTENNA.
Industry payments across WA — which companies pay providers there.
